These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

576 related items for PubMed ID: 8587197

  • 1. [Analysis of tumor rejection antigen peptides recognized by specific CTL].
    Uenaka A, Nakayama E.
    Nihon Rinsho; 1996 Jan; 54(1):242-9. PubMed ID: 8587197
    [Abstract] [Full Text] [Related]

  • 2. Rejection antigen peptides on BALB/c RL male 1 leukemia recognized by cytotoxic T lymphocytes: derivation from the normally untranslated 5' region of the c-akt proto-oncogene activated by long terminal repeat.
    Wada H, Matsuo M, Uenaka A, Shimbara N, Shimizu K, Nakayama E.
    Cancer Res; 1995 Nov 01; 55(21):4780-3. PubMed ID: 7585504
    [Abstract] [Full Text] [Related]

  • 3. [Tumor rejection antigen and cancer immunotherapy].
    Matsutake T, Nakayama E.
    Gan To Kagaku Ryoho; 1995 Nov 01; 22(13):1871-7. PubMed ID: 7487115
    [Abstract] [Full Text] [Related]

  • 4. Analysis of MAGE-3-specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patients.
    Valmori D, Liénard D, Waanders G, Rimoldi D, Cerottini JC, Romero P.
    Cancer Res; 1997 Feb 15; 57(4):735-41. PubMed ID: 9044853
    [Abstract] [Full Text] [Related]

  • 5. Diversity of the fine specificity displayed by HLA-A*0201-restricted CTL specific for the immunodominant Melan-A/MART-1 antigenic peptide.
    Valmori D, Gervois N, Rimoldi D, Fonteneau JF, Bonelo A, Liénard D, Rivoltini L, Jotereau F, Cerottini JC, Romero P.
    J Immunol; 1998 Dec 15; 161(12):6956-62. PubMed ID: 9862730
    [Abstract] [Full Text] [Related]

  • 6. Identification of Meth A sarcoma-derived class I major histocompatibility complex-associated peptides recognized by a specific CD8+ cytotoxic T lymphocyte.
    Frassanito MA, Mayordomo JI, DeLeo RM, Storkus WJ, Lotze MT, DeLeo AB.
    Cancer Res; 1995 Jan 01; 55(1):124-8. PubMed ID: 7528638
    [Abstract] [Full Text] [Related]

  • 7. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues.
    Valmori D, Fonteneau JF, Lizana CM, Gervois N, Liénard D, Rimoldi D, Jongeneel V, Jotereau F, Cerottini JC, Romero P.
    J Immunol; 1998 Feb 15; 160(4):1750-8. PubMed ID: 9469433
    [Abstract] [Full Text] [Related]

  • 8. [Cancer vaccine therapy using peptides derived from tumor-rejection antigens].
    Akiyoshi T.
    Gan To Kagaku Ryoho; 1997 Mar 15; 24(5):511-9. PubMed ID: 9087280
    [Abstract] [Full Text] [Related]

  • 9. [Melanoma antigen genes(MAGE) and malignant tumors].
    Xu JZ, Lin S.
    Ai Zheng; 2003 Sep 15; 22(9):1001-4. PubMed ID: 12969539
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Localization of two cytotoxic T lymphocyte epitopes and three anchoring residues on a single nonameric peptide that binds to H-2Ld and is recognized by cytotoxic T lymphocytes against mouse tumor P815.
    Van den Eynde B, Mazarguil H, Lethé B, Laval F, Gairin JE.
    Eur J Immunol; 1994 Nov 15; 24(11):2740-5. PubMed ID: 7525302
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3.
    van der Bruggen P, Bastin J, Gajewski T, Coulie PG, Boël P, De Smet C, Traversari C, Townsend A, Boon T.
    Eur J Immunol; 1994 Dec 15; 24(12):3038-43. PubMed ID: 7805731
    [Abstract] [Full Text] [Related]

  • 14. Cytolytic T lymphocytes recognize an antigen encoded by MAGE-A10 on a human melanoma.
    Huang LQ, Brasseur F, Serrano A, De Plaen E, van der Bruggen P, Boon T, Van Pel A.
    J Immunol; 1999 Jun 01; 162(11):6849-54. PubMed ID: 10352307
    [Abstract] [Full Text] [Related]

  • 15. Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1.
    Chaux P, Luiten R, Demotte N, Vantomme V, Stroobant V, Traversari C, Russo V, Schultz E, Cornelis GR, Boon T, van der Bruggen P.
    J Immunol; 1999 Sep 01; 163(5):2928-36. PubMed ID: 10453041
    [Abstract] [Full Text] [Related]

  • 16. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1.
    Rivoltini L, Kawakami Y, Sakaguchi K, Southwood S, Sette A, Robbins PF, Marincola FM, Salgaller ML, Yannelli JR, Appella E.
    J Immunol; 1995 Mar 01; 154(5):2257-65. PubMed ID: 7868898
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Detection of naturally processed and HLA-A1-presented melanoma T-cell epitopes defined by CD8(+) T-cells' release of granulocyte-macrophage colony-stimulating factor but not by cytolysis.
    Maeurer MJ, Martin D, Elder E, Storkus WJ, Lotze MT.
    Clin Cancer Res; 1996 Jan 01; 2(1):87-95. PubMed ID: 9816095
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.